Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes

Published:2016-07-12 Issue:11 Volume:18 Page:1138-1142
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wysham Carol¹,Guerci Bruno²,D'Alessio David³,Jia Nan⁴,Botros Fady T.⁴

Affiliation:

1. University of Washington; Rockwood Center for Diabetes and Endocrinology; Spokane Washington

2. University of Lorraine and the Department of Diabetology; Metabolic Diseases and Nutrition, Brabois Adult Hospital, CHRU of Nancy; Vandœuvre-lès-Nancy France

3. Duke University School of Medicine; Department of Endocrinology, Duke Molecular Physiology Institute; Durham North Carolina

4. Eli Lilly and Company; Indianapolis Indiana

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12702/fullpdf

Reference18 articles.

1. Indianapolis, IN Lilly USA, LLC 2014

2. Houten, The Netherlands Eli Lilly and Company 2014

3. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study;Blonde;Lancet,2015

4. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial;Dungan;Lancet,2014

5. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2);Giorgino;Diabetes Care,2015

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus;Endocrine;2024-08-23

2. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review;Communications Medicine;2023-10-05

3. Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors;2023-04-22

4. Predictors of Metformin Failure: Repurposing Electronic Health Record Data to Identify High-Risk Patients;The Journal of Clinical Endocrinology & Metabolism;2023-01-07

5. Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study;Diabetes Therapy;2022-03-13